Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 04/30
(Values in U.S. thousands)
| 10-2025 | 07-2025 | 04-2025 | 01-2025 | 10-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,703 | -2,703 | -4,515 | -3,375 | -2,390 |
| Depreciation Amortization | 55 | 28 | 51 | 38 | 25 |
| Other Working Capital | 39 | 269 | -2,439 | -2,795 | -2,263 |
| Other Operating Activity | 74 | 43 | 335 | 253 | 172 |
| Operating Cash Flow | $-3,534 | $-2,363 | $-6,568 | $-5,880 | $-4,456 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -300 | -90 | -90 |
| Investing Cash Flow | $N/A | $N/A | $-300 | $-90 | $-90 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 0 | N/A | 2,704 | 1,863 | 1,174 |
| Other Financing Activity | 4,035 | 4,035 | 7,737 | 7,089 | 7,089 |
| Financing Cash Flow | $4,035 | $4,035 | $10,441 | $8,952 | $8,263 |
| Beginning Cash Position | 3,949 | 3,949 | 376 | 376 | 376 |
| End Cash Position | 4,449 | 5,621 | 3,949 | 3,358 | 4,093 |
| Net Cash Flow | $501 | $1,672 | $3,573 | $2,982 | $3,717 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,534 | -2,363 | -6,568 | -5,880 | -4,456 |
| Capital Expenditure | N/A | N/A | -300 | -90 | -90 |
| Free Cash Flow | -3,534 | -2,363 | -6,868 | -5,970 | -4,546 |